LEN, which has demonstrated clinical efficacy in multiple myeloma and striking activity in myelodysplastic syndrome (MDS), can upregulate RUNX1 in hematopoietic stem and progenitor cells (24). Here, RUNX1 is linked to plasma cell myeloma.